Literature DB >> 26391547

Combined Therapies for Lysosomal Storage Diseases.

M Gabig-Cimińska, J Jakóbkiewicz-Banecka, M Malinowska, A Kloska, E Piotrowska, I Chmielarz, M Moskot, A Węgrzyn, G Węgrzyn1.   

Abstract

Lysosomal storage diseases (LSDs) is a group consisting of over 50 disorders caused mostly by dysfunctions of lysosomal proteins and resultant accumulation of particular compounds inside cells and extracellular volumes in affected organisms. Genetic diseases are among the most difficult targets for medical treatment. Nevertheless, understanding of molecular bases of LSDs made it possible to develop novel procedures of treatment, employing molecular medicine. Although various therapeutic approaches have been proposed, and some of them were introduced into clinical practice, none of them was found to be effective in correcting all symptoms in treated patients. Central nervous system and skeleton appear to be the most difficult targets to be improved. Therefore, a proposal appeared that perhaps no single therapeutic procedure may be fully effective in treatment of LSD patients, and only combination of two or more approaches could be a successful therapy. In this review, we present and discuss current stage of various combination therapies for LSDs, based on already available published data.

Entities:  

Mesh:

Year:  2015        PMID: 26391547     DOI: 10.2174/1566524015666150921105658

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  8 in total

Review 1.  Small molecules as therapeutic agents for inborn errors of metabolism.

Authors:  Leslie Matalonga; Laura Gort; Antonia Ribes
Journal:  J Inherit Metab Dis       Date:  2016-12-13       Impact factor: 4.982

Review 2.  Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem.

Authors:  Shannon L Macauley
Journal:  Pediatr Endocrinol Rev       Date:  2016-06

Review 3.  Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders.

Authors:  Maria Francisca Coutinho; Juliana Inês Santos; Sandra Alves
Journal:  Int J Mol Sci       Date:  2016-07-04       Impact factor: 5.923

Review 4.  Genetic Substrate Reduction Therapy: A Promising Approach for Lysosomal Storage Disorders.

Authors:  Maria Francisca Coutinho; Juliana Inês Santos; Liliana Matos; Sandra Alves
Journal:  Diseases       Date:  2016-11-09

5.  Nonsteroidal anti-inflammatory drugs modulate cellular glycosaminoglycan synthesis by affecting EGFR and PI3K signaling pathways.

Authors:  Paweł Mozolewski; Marta Moskot; Joanna Jakóbkiewicz-Banecka; Grzegorz Węgrzyn; Katarzyna Bocheńska; Bogdan Banecki; Magdalena Gabig-Cimińska
Journal:  Sci Rep       Date:  2017-02-27       Impact factor: 4.379

6.  Transcriptomic Changes Related to Cellular Processes with Particular Emphasis on Cell Activation in Lysosomal Storage Diseases from the Group of Mucopolysaccharidoses.

Authors:  Estera Rintz; Lidia Gaffke; Magdalena Podlacha; Joanna Brokowska; Zuzanna Cyske; Grzegorz Węgrzyn; Karolina Pierzynowska
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

Review 7.  Lysosomal Storage Disease-Associated Neuropathy: Targeting Stable Nucleic Acid Lipid Particle (SNALP)-Formulated siRNAs to the Brain as a Therapeutic Approach.

Authors:  Maria Francisca Coutinho; Juliana Inês Santos; Liliana S Mendonça; Liliana Matos; Maria João Prata; Amália S Jurado; Maria C Pedroso de Lima; Sandra Alves
Journal:  Int J Mol Sci       Date:  2020-08-10       Impact factor: 5.923

Review 8.  One drug to treat many diseases: unlocking the economic trap of rare diseases.

Authors:  Karolina Pierzynowska; Teresa Kamińska; Grzegorz Węgrzyn
Journal:  Metab Brain Dis       Date:  2020-09-14       Impact factor: 3.584

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.